CSPC Pharmaceutical Group Limited (CSPCY) Stock Price & Analysis
CSPC Pharmaceutical Group Limited (CSPCY) — price $3.97 (-0.75%), as of the Nov 19, 2026 trading session; market cap $11.3B.
Educational signal · not a buy or sell recommendation · How to read this
CSPC Pharmaceutical Group Limited · CSPCY
CSPC Pharmaceutical Group Limited is a leading Chinese pharmaceutical company engaged in the research, development, manufacturing, and distribution of a wide array of pharmaceutical products.
Price as of Nov 19, 2026
Key Statistics
Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.
Thousands of the 20,000+ US stocks here carry a MoonshotScore.
Scored companies in the same industry:
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $3.97 | |
| Change on the day | -0.75% | |
| 52-week range | $3.26 – $5.46 | |
| Market capitalisation | $11.3B | — |
| Price / earnings (trailing) | 10.17 | |
| Shares traded on the day | 350 |
Price & events
Other perspectives
Council score for CSPC Pharmaceutical Group (CSPCY): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Legends Council
3 lenses, 3 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 19, 2026
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 10, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is CSPC Pharmaceutical Group (CSPCY), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. CSPC Pharmaceutical Group Limited (CSPCY) is the company analyzed here. It employs 19,700 people and is led by Lei Cai. In Q2 FY2026 it reported revenue of CN¥18.39B and net income of CN¥6.03B. The market values it at $11.3B.
What do the latest results show for CSPC Pharmaceutical Group (CSPCY)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of CN¥18.39B.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | CN¥18.39B | CN¥6.03B | CN¥2.12 (diluted) |
| Q4 FY2025 | CN¥12.49B | CN¥1.31B | CN¥0.48 (diluted) |
| Q2 FY2025 | CN¥1.67B | CN¥321M | CN¥0.11 (diluted) |
| Q4 FY2024 | CN¥13.70B | CN¥1.33B | CN¥0.44 (diluted) |
What are the financial strengths and risks for CSPC Pharmaceutical Group (CSPCY)?
Short answer · as of
The distress and quality screens read Altman Z 4.74 · Piotroski F 6. Trailing ratios: ROE 20.7% · ROA 13.1% · current ratio 2.14 · earnings yield 9.6% · free-cash-flow yield 16.0%.
The records behind this page
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held CSPCY in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported CSPCY in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
Investor Questions: CSPCY Stock
These answers are editorial: 1 of these 8 answers is drawn from the CSPCY research dossier (written Jun 14, 2026 by gpt-4o-mini); the other 7 are question templates that restate figures shown above. Figures in this section are not part of the source register.
Is CSPCY a good stock to buy?
Stock Expert AI does not rate CSPCY buy, sell or hold. CSPC Pharmaceutical Group Limited has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the CSPCY stock price today?
The last price recorded for CSPC Pharmaceutical Group Limited (CSPCY), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What are the main risks for CSPCY?
CSPC Pharmaceutical Group Limited faces several risks, including potential regulatory challenges that could impact product approvals and market access. Additionally, ongoing competition from both domestic and international pharmaceutical companies may affect its market share. Economic fluctuations could also influence healthcare spending patterns, impacting demand for CSPC's products.
What are the key factors to evaluate for CSPCY?
Evaluate CSPCY on fundamentals, analyst consensus, and risk factors. To weigh it, start with the trailing P/E under Price & valuation on this page. Expansion of Oncology Portfolio: CSPC's oncology segment, particularly its products Duomeisu and Keaili, is poised for significant growth due to rising cancer incidence rates and increasing healthcare expenditures. Not financial advice.
How frequently does CSPCY data refresh on this page?
CSPCY's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven CSPCY's recent stock price performance?
CSPC Pharmaceutical Group Limited (CSPCY) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Strong market presence in China and expanding international operations. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider CSPCY overvalued or undervalued right now?
The trailing P/E of CSPC Pharmaceutical Group Limited (CSPCY) is listed under Price & valuation on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research CSPCY before investing?
Before investing in CSPC Pharmaceutical Group Limited (CSPCY), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Machine-generated analysis by Stock Expert AI — model gpt-4o-mini, generated Jun 14, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 14 figures on this page — 8 from Financial Modeling Prep (FMP) and 6 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com